Effect of a dopaminergic drug on LH, FSH and prolactin levels in PCO syndrome

P. L. Venturini, M. P. Alibrandi, S. Costantini, G. Gaggero, L. Penna, M. Valenzano, N. Ragni

Research output: Contribution to journalArticle

Abstract

Although the role of dopaminergic system in the regulation of LH secretion is not fully established, the weight of evidence supports an inhibitory role. Yen (1980) showed that dopamine infusion decreases plasma LH levels in women with PCO Syndrome. It is known that Nomifensine activates central dopaminergic neurotransmission via presynaptic events without directly affecting DA receptors sites. In 15 polycystic ovary syndrome cases, Nomifensine failed to decrease basal and GnRH stimulated LH levels, although PRL levels were lowered. Although the increased dopaminergic activity was showed by PRL decrease, central dopaminergic activation had no effect on LH secretion. The finding may be explained by the predominant effect of DA system on physiological control of PRL secretion compared with the effects on LH secretion. Moreover in PCO patients pituitary sensitivity to GnRH is increased and in this pathological condition activation of central DA system may not lower the LH level. These results showed that Nomifensine induced central dopamine activation but did not influence basal and stimulated LH levels in PCO Syndrome.

Original languageEnglish
Pages (from-to)295-297
Number of pages3
JournalActa Europaea Fertilitatis
Volume12
Issue number3
Publication statusPublished - 1981

Fingerprint

Nomifensine
Dopamine Agents
Prolactin
Gonadotropin-Releasing Hormone
Dopamine
Polycystic Ovary Syndrome
Synaptic Transmission
Weights and Measures

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Venturini, P. L., Alibrandi, M. P., Costantini, S., Gaggero, G., Penna, L., Valenzano, M., & Ragni, N. (1981). Effect of a dopaminergic drug on LH, FSH and prolactin levels in PCO syndrome. Acta Europaea Fertilitatis, 12(3), 295-297.

Effect of a dopaminergic drug on LH, FSH and prolactin levels in PCO syndrome. / Venturini, P. L.; Alibrandi, M. P.; Costantini, S.; Gaggero, G.; Penna, L.; Valenzano, M.; Ragni, N.

In: Acta Europaea Fertilitatis, Vol. 12, No. 3, 1981, p. 295-297.

Research output: Contribution to journalArticle

Venturini, PL, Alibrandi, MP, Costantini, S, Gaggero, G, Penna, L, Valenzano, M & Ragni, N 1981, 'Effect of a dopaminergic drug on LH, FSH and prolactin levels in PCO syndrome', Acta Europaea Fertilitatis, vol. 12, no. 3, pp. 295-297.
Venturini PL, Alibrandi MP, Costantini S, Gaggero G, Penna L, Valenzano M et al. Effect of a dopaminergic drug on LH, FSH and prolactin levels in PCO syndrome. Acta Europaea Fertilitatis. 1981;12(3):295-297.
Venturini, P. L. ; Alibrandi, M. P. ; Costantini, S. ; Gaggero, G. ; Penna, L. ; Valenzano, M. ; Ragni, N. / Effect of a dopaminergic drug on LH, FSH and prolactin levels in PCO syndrome. In: Acta Europaea Fertilitatis. 1981 ; Vol. 12, No. 3. pp. 295-297.
@article{7b3a0a988351407483e04c4f0084de4b,
title = "Effect of a dopaminergic drug on LH, FSH and prolactin levels in PCO syndrome",
abstract = "Although the role of dopaminergic system in the regulation of LH secretion is not fully established, the weight of evidence supports an inhibitory role. Yen (1980) showed that dopamine infusion decreases plasma LH levels in women with PCO Syndrome. It is known that Nomifensine activates central dopaminergic neurotransmission via presynaptic events without directly affecting DA receptors sites. In 15 polycystic ovary syndrome cases, Nomifensine failed to decrease basal and GnRH stimulated LH levels, although PRL levels were lowered. Although the increased dopaminergic activity was showed by PRL decrease, central dopaminergic activation had no effect on LH secretion. The finding may be explained by the predominant effect of DA system on physiological control of PRL secretion compared with the effects on LH secretion. Moreover in PCO patients pituitary sensitivity to GnRH is increased and in this pathological condition activation of central DA system may not lower the LH level. These results showed that Nomifensine induced central dopamine activation but did not influence basal and stimulated LH levels in PCO Syndrome.",
author = "Venturini, {P. L.} and Alibrandi, {M. P.} and S. Costantini and G. Gaggero and L. Penna and M. Valenzano and N. Ragni",
year = "1981",
language = "English",
volume = "12",
pages = "295--297",
journal = "Acta Europaea Fertilitatis",
issn = "0587-2421",
number = "3",

}

TY - JOUR

T1 - Effect of a dopaminergic drug on LH, FSH and prolactin levels in PCO syndrome

AU - Venturini, P. L.

AU - Alibrandi, M. P.

AU - Costantini, S.

AU - Gaggero, G.

AU - Penna, L.

AU - Valenzano, M.

AU - Ragni, N.

PY - 1981

Y1 - 1981

N2 - Although the role of dopaminergic system in the regulation of LH secretion is not fully established, the weight of evidence supports an inhibitory role. Yen (1980) showed that dopamine infusion decreases plasma LH levels in women with PCO Syndrome. It is known that Nomifensine activates central dopaminergic neurotransmission via presynaptic events without directly affecting DA receptors sites. In 15 polycystic ovary syndrome cases, Nomifensine failed to decrease basal and GnRH stimulated LH levels, although PRL levels were lowered. Although the increased dopaminergic activity was showed by PRL decrease, central dopaminergic activation had no effect on LH secretion. The finding may be explained by the predominant effect of DA system on physiological control of PRL secretion compared with the effects on LH secretion. Moreover in PCO patients pituitary sensitivity to GnRH is increased and in this pathological condition activation of central DA system may not lower the LH level. These results showed that Nomifensine induced central dopamine activation but did not influence basal and stimulated LH levels in PCO Syndrome.

AB - Although the role of dopaminergic system in the regulation of LH secretion is not fully established, the weight of evidence supports an inhibitory role. Yen (1980) showed that dopamine infusion decreases plasma LH levels in women with PCO Syndrome. It is known that Nomifensine activates central dopaminergic neurotransmission via presynaptic events without directly affecting DA receptors sites. In 15 polycystic ovary syndrome cases, Nomifensine failed to decrease basal and GnRH stimulated LH levels, although PRL levels were lowered. Although the increased dopaminergic activity was showed by PRL decrease, central dopaminergic activation had no effect on LH secretion. The finding may be explained by the predominant effect of DA system on physiological control of PRL secretion compared with the effects on LH secretion. Moreover in PCO patients pituitary sensitivity to GnRH is increased and in this pathological condition activation of central DA system may not lower the LH level. These results showed that Nomifensine induced central dopamine activation but did not influence basal and stimulated LH levels in PCO Syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0019843075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019843075&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 295

EP - 297

JO - Acta Europaea Fertilitatis

JF - Acta Europaea Fertilitatis

SN - 0587-2421

IS - 3

ER -